What is Carterra?
Carterra is at the forefront of antibody screening and characterization, leveraging patented microfluidic technology and Surface Plasmon Resonance (SPR) imaging. Their advanced platform, including the Carterra Vega, Ultra, and LSA systems, enables rapid and efficient screening of extensive compound and antibody libraries. The company's solutions are critical for biopharmaceutical companies and research institutions engaged in therapeutic areas such as immuno-oncology, infectious diseases, and vaccine development, facilitating precise epitope mapping and binding kinetics analysis to enhance the drug discovery pipeline.
How much funding has Carterra raised?
Carterra has raised a total of $17M across 3 funding rounds:
Unspecified
$10M
Other Financing Round
$6M
Debt
$1M
Unspecified (2018): $10M with participation from Telegraph Hill Partners
Other Financing Round (2020): $6M led by Telegraph Hill Partners and Ballast Point Ventures
Debt (2020): $1M supported by PPP
Key Investors in Carterra
Telegraph Hill Partners
Telegraph Hill Partners is a venture capital firm founded in 2001, based in San Francisco, CA, that specializes in investing in commercial-stage life science, medical technology, and healthcare companies.
Ballast Point Ventures
Ballast Point Ventures is a late venture and early growth equity investor focused on providing expansion capital to established, rapidly growing private companies, primarily in the Southeast and Texas, with a focus on software, tech-enabled services, and healthcare.
PPP
Public-Private Partnership
What's next for Carterra?
With the recent infusion of major strategic capital, Carterra is poised to further solidify its market position. The company's focus on enhancing the efficiency and speed of drug discovery through its innovative screening and characterization tools aligns with the growing demand for faster therapeutic development. Future growth is likely to involve expanding its technological capabilities, broadening its client base within the biopharmaceutical sector, and potentially exploring new therapeutic applications for its platform. This strategic investment signals strong confidence in Carterra's technology and its potential to significantly impact the future of biopharmaceutical research and development.
See full Carterra company page
